Mayer is leading Gilead Sciences Inc.'s representation of its oncology and HIV portfolios - a significant part of the company's patent work.
Gilead claims approximately 70 percent of the HIV drug market. Mayer also led the intellectual property due diligence for Gilead's $510 million acquisition last year of Canada-based YM BioSciences, a cancer therapeutics company. "This is illustrative of the work I'm doing," she said. "The folks in the Valley...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In